Diagnosis and Management of Headache: A Review
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Approximately 90% of people in the US experience headache during their lifetime. Migraine is the second leading cause of years lived with disability worldwide. OBSERVATIONS: Primary headache disorders are defined as headaches that are unrelated to an underlying medical condition and are categorized into 4 groups: migraine, tension-type headache, trigeminal autonomic cephalalgias, and other primary headache disorders. Studies evaluating prevalence in more than 100 000 people reported that tension-type headache affected 38% of the population, while migraine affected 12% and was the most disabling. Secondary headache disorders are defined as headaches due to an underlying medical condition and are classified according to whether they are due to vascular, neoplastic, infectious, or intracranial pressure/volume causes. Patients presenting with headache should be evaluated to determine whether their headache is most likely a primary or a secondary headache disorder. They should be evaluated for symptoms or signs that suggest an urgent medical problem such as an abrupt onset, neurologic signs, age 50 years and older, presence of cancer or immunosuppression, and provocation by physical activities or postural changes. Acute migraine treatment includes acetaminophen, nonsteroidal anti-inflammatory drugs, and combination products that include caffeine. Patients not responsive to these treatments may require migraine-specific treatments including triptans (5-HT1B/D agonists), which eliminate pain in 20% to 30% of patients by 2 hours, but are accompanied by adverse effects such as transient flushing, tightness, or tingling in the upper body in 25% of patients. Patients with or at high risk for cardiovascular disease should avoid triptans because of vasoconstrictive properties. Acute treatments with gepants, antagonists to receptors for the inflammatory neuropeptide calcitonin gene-related peptide, such as rimegepant or ubrogepant, can eliminate headache symptoms for 2 hours in 20% of patients but have adverse effects of nausea and dry mouth in 1% to 4% of patients. A 5-HT1F agonist, lasmiditan, is also available for acute migraine treatment and appears safe in patients with cardiovascular risk factors. Preventive treatments include antihypertensives, antiepileptics, antidepressants, calcitonin gene-related peptide monoclonal antibodies, and onabotulinumtoxinA, which reduce migraine by 1 to 3 days per month relative to placebo. CONCLUSIONS AND RELEVANCE: Headache disorders affect approximately 90% of people during their lifetime. Among primary headache disorders, migraine is most debilitating and can be treated acutely with analgesics, nonsteroidal anti-inflammatory drugs, triptans, gepants, and lasmiditan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
Buse, D. C., Manack, A., Serrano, D., Turkel, C., & Lipton, R. B. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.192492 · Cited by 622
Gonçalves, A. L., Martini Ferreira, A., Ribeiro, R. T., Zukerman, E., Cipolla-Neto, J., & Peres, M. F. P. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313458 · Cited by 169
Cited by
Paracetamol: A Review of Guideline Recommendations
Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153420 · Cited by 208
“In the last few months, new published studies report the safe use of paracetamol in patients with chronic kidney disease [147], the significant efficacy of paracetamol for post-arthroplasty pain [148], the lesser efficacy of paracetamol than ibuprofen for post-laminectomy pain [149], the opioid-sparing effects of para…”
BackgroundBurch, R. C., Ailani, J., & Robbins, M. S. (2022) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14245 · Cited by 50
Self-citationPerrot, S., Eschalier, A., Desmeules, J., Lanteri-Minet, M., & Attal, N. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2076475 · Cited by 6
Metadata
- Authors
- Robbins, M. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-11
- Volume
- 325
- Issue
- 18
- Pages
- 1874
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3163785023
- Cited by
- 219
- References
- 4
- FWCI
- 20.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Management of Headache: A Review. https://app.cochat.ai/papers/10.1001/jama.2021.1640
- The paper
- Robbins, M. S. (2021). Diagnosis and Management of Headache: A Review. JAMA. https://doi.org/10.1001/jama.2021.1640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.